Epilepsy
Therapeutic area
Neurology
Rare disease
No
- Definition
- A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Epilepsy
- Therapeutic area
- Neurology
- epilepsy
- Epilepsy (Treatment Refractory)
- Epilepsy and Focal Cortical Dysplasia II
- Epilepsy, Absence
- Epilepsy, Benign Neonatal
- Epilepsy, Cryptogenic
- Epilepsy, Drug Refractory
- Epilepsy, Drug Resistant
- Epilepsy, Focal Seizures, Partial Seizures
- Epilepsy, Intractable
- Epilepsy, Localization Related
- Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
- Epilepsy, Motor Partial
- Epilepsy, Partial Seizures
- Epilepsy, Primary Generalized Tonic-Clonic Seizures
- Epilepsy, Refractory
- Epilepsy, Unspecified, Intractable
- Epilepsy, Unspecified, Pharmacologically Resistant
- Epilepsy, Unspecified, Refractory (Medically)
- epilepsy,cognition
- Epilepsy，Cognition
- Refractory Epilepsy
- seizure disorder
- Seizure Disorder, Partial
- Seizure Disorders
- All therapeutic areas
- Neurology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0005027
- Parent condition
- MONDO:0005560
Related records
Broader conditions (6)
- Brain disorder
- Central nervous system disorder
- Disease
- Disease by body system or component
- Human disease
- Nervous system disorder
Narrower conditions (360)
- Acquired developmental and epileptic encephalopathy
- Acquired sleep-related hypermotor epilepsy
- Action myoclonus-renal failure syndrome
- Acute encephalopathy with biphasic seizures and late reduced diffusion
- Adolescence-adult electroclinical syndrome
- Antibody mediated epilepsy
- Atypical childhood epilepsy with centrotemporal spikes
- Audiogenic seizures
- Autoimmune epilepsy
- Autosomal dominant epilepsy with auditory features
- Autosomal dominant nocturnal frontal lobe epilepsy 1
- Autosomal dominant nocturnal frontal lobe epilepsy 2
- Autosomal dominant nocturnal frontal lobe epilepsy 3
- Autosomal dominant nocturnal frontal lobe epilepsy 4
- Autosomal dominant nocturnal frontal lobe epilepsy 5
- Autosomal recessive cerebellar ataxia - epilepsy - intellectual disability syndrome
- Autosomal recessive spinocerebellar ataxia 12
- Autosomal recessive spinocerebellar ataxia 15
- Benign adult familial myoclonic epilepsy
- Benign familial infantile epilepsy
Trials (1,993)
- " Virtual Brain "-Based Interpretation of Electrophysiological Signals in Epilepsy
- 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
- 3-Dimensional Accelerometer Sub-Study
- 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
- 5-SENSE Score Validation Study
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
- A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
- A Biosensor for Tracking Seizures: Linking a Wrist Accelerometer to an Online Epilepsy Diary
- A China RWS to Evaluate the Effectiveness and Safety of Perampanel as an add-on Treatment for Epileptic Seizure
- A Clinical Decision Aid for Diagnosing Transient Loss of Consciousness
- A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
- A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
- A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
- A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
- A Clinical Trial With a Self-controlled, Multicenter, Pediatric EEG Intelligent Analysis System to Assist in Diagnosis
- A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy
- A Comparison of a Currently Marketed Hearing Aid Programmed With Two Different Fitting Methods
- A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment
Approved drugs (55)
- Acetazolamide
- Barbexaclone
- Beclamide
- Brivaracetam
- Cannabidiol
- Carbamazepine
- Cenobamate
- Clonazepam
- Diazepam
- Divalproex sodium
- Eslicarbazepine
- Eslicarbazepine acetate
- Eterobarb
- Ethosuximide
- Ethotoin
- Ezogabine
- Felbamate
- Fenfluramine
- Fenfluramine hydrochloride
- Fosphenytoin
Drugs in development (106)
- 2-deoxy-D-glucose Phase 2
- Acetylcysteine Phase 2
- Albumin human Phase 1
- Allopurinol Phase 2
- Alprazolam Phase 2
- Ameltolide Phase 1
- Apinocaltamide Phase 2
- Apomorphine Phase 3
- Ascorbic acid Phase 2
- Ataluren Phase 2
- Atorvastatin Phase 1
- Azetukalner Phase 1
- Becampanel Phase 2
- Belnacasan Phase 2
- Cannabidivarin Phase 1
- Cannabinol Phase 3
- Carabersat Phase 2
- Carisbamate Phase 3
- Carvedilol Phase 2
- Cholecalciferol Phase 3
Other linked drugs (13)
- Albendazole
- Carbon monoxide
- Ciprofloxacin
- Dexamethasone
- Glimepiride
- Glyburide
- Lorcaserin
- Lovastatin
- Propofol
- Ralitoline
- Remifentanil
- Verapamil
- Verapamil hydrochloride